S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C.
Yamada Y, et al. Among authors: takahashi s.
Ann Oncol. 2018 Mar 1;29(3):624-631. doi: 10.1093/annonc/mdx816.
Ann Oncol. 2018.
PMID: 29293874
Free PMC article.
Clinical Trial.